Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.

Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA.

Circulation. 2010 Oct 12;122(15):1478-87. doi: 10.1161/CIRCULATIONAHA.110.947960. Epub 2010 Sep 27.

2.
5.

Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report.

Schnell-Inderst P, Schwarzer R, Göhler A, Grandi N, Grabein K, Stollenwerk B, Manne J, Klauss V, Siebert U, Wasem J.

Int J Technol Assess Health Care. 2010 Jan;26(1):30-9. doi: 10.1017/S0266462309990870.

PMID:
20059778
6.

Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.

Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.

Circulation. 2007 May 8;115(18):2398-409. Epub 2007 Apr 23.

8.

Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals.

Rosendo AB, Lima LO, Dal-Pizzol F, Almeida S.

Inflammation. 2010 Aug;33(4):244-50. doi: 10.1007/s10753-009-9178-3.

PMID:
20084446
9.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

11.

Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events.

Schnell-Inderst P, Schwarzer R, Göhler A, Grandi N, Grabein K, Stollenwerk B, Klauß V, Wasem J, Siebert U.

GMS Health Technol Assess. 2009 May 12;5:Doc06. doi: 10.3205/hta000068.

12.

Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.

Slejko JF, Page RL 2nd, Sullivan PW.

Curr Med Res Opin. 2010 Oct;26(10):2485-97. doi: 10.1185/03007995.2010.516994.

PMID:
20828360
13.

The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.

Albert MA, Staggers J, Chew P, Ridker PM; PRINCE Investigators.

Am Heart J. 2001 Jun;141(6):893-8.

PMID:
11376301
14.

Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.

Blum A, Costello R, Samsel L, Zalos G, McCoy P, Csako G, Waclawiw MA, Cannon RO 3rd.

Isr Med Assoc J. 2009 Oct;11(10):602-5.

15.

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.

PMID:
10819699
16.

Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?

Mahoney EM.

Circulation. 2010 Oct 12;122(15):1446-8. doi: 10.1161/CIRCULATIONAHA.110.981944. Epub 2010 Sep 27. No abstract available.

17.

Statin therapy improves cardiovascular outcome of patients with peripheral artery disease.

Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, Rumpold H, Wagner O, Minar E.

Eur Heart J. 2004 May;25(9):742-8.

PMID:
15120884
18.

Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting.

Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC.

Circ J. 2005 Dec;69(12):1477-83.

19.

Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.

Bays HE, Davidson M, Jones MR, Abby SL.

Am J Cardiol. 2006 Apr 15;97(8):1198-205. Epub 2006 Mar 3. Erratum in: Am J Cardiol. 2006 Aug 1;98(3):428.

PMID:
16616026
20.

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators.

Circulation. 2007 Mar 27;115(12):1528-36. Epub 2007 Mar 19.

Supplemental Content

Support Center